RE:RE:Theratechnologies Receives Refusal to File Letter for Trogar we were aware that the approval of this sBLA for Trogarzo
® IM administration could be challenging based on the
results shared in October 2023 from the TMB-302 study, even though viral suppression was maintained throughout the study,” said Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer at Theratechnologies. “We will now assess our options regarding this application.”
if you know it will be complicated...be sure before sending it...it makes sense